Using an alpha-1A-adrengic receptor agonist, dabuzalgron, as a therapeutic treatment for cardiomyopathy and heart failure.
As potentially debilitating and life-threatening conditions, cardiomyopathy and heart failure (HF) are major medical problems worldwide. In the US alone, nearly 6 million people suffer from HF. As the incidence of these diseases increases with age, the burden of these diseases will likely only increase as elderly populations continue to grow. Around 1 million American patients are hospitalized with HF each year and current treatment options are ineffective in keeping these patients out of the hospital as readmission rates within 6 months of discharge remain high.
This new treatment improves upon current cardiomyopathy and heart failure drugs in several ways, including:
Additionally, this drug is attractive to develop for heart disease as it is:
Dr. Paul Simpson Jr. at University of California, San Francisco and Dr. Brain C Jensen at University of North Carolina - Chapel Hill have identified and developed a new indication for dabuzalgron: prevention and treatment of cardiomyopathy and heart failure. Dabuzalgron is an alpha-1A-adrenergic receptor agonist that can stimulate smooth muscle contraction in higher doses; however, in this invention, the drug is used at doses below those found to have an effect on smooth muscle contraction and blood pressure. These researchers have shown that dabuzalgron leads to a variety of beneficial intracellular processes in heart muscle cells, including mechanisms that protect the cell from injury or death. Dabuzalgron also could be used to protect the heart from cancer-induced cardiomyopathy.
To develop & commercialize the technology as a novel heart disease therapeutic
Animal data available under CDA/NDA
|United States Of America||Published Application||20190117623||04/25/2019||2015-081|
|European Patent Office||Published Application||EP3419666||01/02/2019||2015-081|
Alpha-1A-adrenergic receptor, Adrenergic receptor agonist, Heart failure, Heart disease, Heart muscle disease, Cardiomyopathy, Myocardial dysfunction